Post by Dr. J. Jean Cui https://lnkd.in/gxWmhqfu
Co-Founder, President/CEO, BlossomHill Therapeutics, Inc.; Co-Founder, CSO, Turning Point Therapeutics, Inc. (10.2013-1.2020); Lead inventor of 3 FDA-approved oncology drugs; Academician, National Academy of Engineering.
Even though expected, but I still feel very emotional when heard the news of Repotrectinib approval by FDA. It is great news that ROS1 positive NSCLC patients have a new option for their treatment. I am grateful for all the support I received. Special thanks go to Dr. Sai-Hong Ignatius Ou who helped develop clinical trial plan from the very beginning for TPX-0005 (i.e. Repotrectinib). I am grateful to the clinicians, patients and their families, Turning Point team members, and investors. I am still on my journey to create more novel drugs that can help patients and save lives. Thank you. https://lnkd.in/g6BAK_td
